ETC-1002 and Ezetimibe Fixed-Dose Combination for Cardiovascular Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular disease, particularly statin therapies, often result in statin-associated muscle symptoms in patients, leading to intolerance and increased cardiovascular risk, and existing cholesterol-lowering drugs can be systemically toxic despite their effectiveness.
Innovation Solution
A fixed-dose combination of ETC-1002 and Ezetimibe, where ETC-1002 directly inhibits hepatic adenosine triphosphate citrate lyase to reduce cholesterol synthesis and increase LDL receptor expression, combined with Ezetimibe to decrease cholesterol absorption, offering a safer and more effective approach to lowering LDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statin therapy is used to treat cardiovascular disease, then cholesterol levels are reduced, but muscle symptoms and intolerance occur in 5% to 29% of patients
Solution Approach 1:
The invention segments the cholesterol-lowering function into two separate mechanisms: one agent (ETC-1002) that inhibits hepatic cholesterol synthesis and another (Ezetimibe) that inhibits intestinal cholesterol absorption. This segmentation allows each agent to work through a different pathway, reducing the likelihood of overlapping toxic effects while maintaining effective cholesterol reduction.
Solution Approach 2:
The invention uses a composite therapeutic approach by combining two different cholesterol-lowering agents with distinct mechanisms of action. ETC-1002 (an ACLY inhibitor) and Ezetimibe (a cholesterol absorption inhibitor) form a composite regimen that achieves synergistic cholesterol reduction while minimizing the muscle toxicity associated with statins.
2Quantity of substance
If new cholesterol-reducing drugs are used to lower LDL-C levels, then cholesterol reduction efficacy is improved, but systemically toxic side effects occur
Solution Approach 1:
The invention introduces ETC-1002 as an intermediary agent that specifically targets hepatic adenosine triphosphate citrate lyase (ACLY) to inhibit cholesterol synthesis. This localized enzymatic inhibition provides effective cholesterol reduction while avoiding the systemic toxicity of other potent cholesterol-lowering drugs through its specific mechanism of action.
Solution Approach 2:
The invention changes the therapeutic parameter from statin-based HMG-CoA reductase inhibition to ACLY inhibition with ETC-1002. This parameter change allows for effective cholesterol synthesis blockade while producing a different safety profile that avoids statin-associated muscle toxicity and other systemic side effects.
3Quantity of substance
If Ezetimibe is used alone to lower cholesterol, then cholesterol absorption is reduced, but it cannot achieve statistically significant impact on major cardiovascular event outcomes
Solution Approach 1:
The invention merges Ezetimibe (which reduces cholesterol absorption) with ETC-1002 (which reduces cholesterol synthesis) to create a combination therapy. This merging of two complementary mechanisms achieves greater than additive cholesterol reduction and provides more reliable cardiovascular outcome benefits than Ezetimibe alone.
Solution Approach 2:
The combination regimen serves multiple functions: Ezetimibe blocks intestinal cholesterol absorption, ETC-1002 blocks hepatic cholesterol synthesis, and together they produce synergistic LDL-C reduction. This multi-functional approach addresses both absorption and synthesis pathways, providing comprehensive cholesterol management and improved cardiovascular outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly reduces LDL-C levels, provides a favorable safety profile, and is more effective than either monotherapy or statin therapy alone, particularly in patients with statin intolerance, while minimizing muscle-related adverse events.
Implementation Method 1
ETC-1002 is an agent that lowers low-density lipoprotein cholesterol (LDL-C) by direct inhibition of hepatic adenosine triphosphate citrate lyase, leading to reduced de novo cholesterol synthesis
Implementation Method 2
Ezetimibe is a compound which lowers cholesterol levels in the body by decreasing cholesterol absorption in the small intestine
Data Source
AI summary
Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.